Filing Flows › Sonoma Pharmaceuticals (SNOA) › Q3 FY26
Sonoma Pharmaceuticals (SNOA) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Feb 10, 2026
Sonoma Pharmaceuticals (SNOA) reported revenue of $4.3M for the third quarter fiscal 2026 (Q3 FY26), +22% from a year earlier and -22% from the quarter before. Operating margin was -15.6%, net loss $819K (18.8% of revenue).
Sonoma Pharmaceuticals, Q3 FY26: revenue $4.3M (+22% year over year), operating margin -15.6%, net loss $819K, operating cash flow −$764K. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.3M | -22% | +22% |
| Operating profit | −$678K | — | — |
| Net earnings | −$819K | — | — |
| Operating cash flow | −$764K | — | -235% |
What changed
Revenue was $4.3M in Q3 FY26, up 22% year over year and down 22% from the previous quarter.
Gross margin was 37.9%, up 2.3 points from Q3 FY25. Operating costs exceeded revenue by $678K, an operating margin of -15.6%. Operating expenses grew 1% against revenue growth of 22%. The fastest-growing cost line was Research & development (+30%). The quarter ended with a net loss of $819K, wider than the previous quarter's $534K loss.
Operating cash flow was −$764K. Non-cash charges added back $34K of depreciation and amortization and $24K of share-based compensation. Capital expenditures of $47K exceeded it, leaving free cash flow of −$811K.
Questions
What was Sonoma Pharmaceuticals' revenue in the third quarter fiscal 2026?
Sonoma Pharmaceuticals (SNOA) reported revenue of $4.3M for the third quarter fiscal 2026 (Q3 FY26), +22% from a year earlier and -22% from the quarter before.
Was Sonoma Pharmaceuticals profitable in the third quarter fiscal 2026?
Operating loss was $678K (-15.6% of revenue) and net loss $819K.